Loading...

Ralph W De Vere White

TitlePROF EMERITUS(WOS)
InstitutionUniversity of California Davis
DepartmentUrology
Address4501 X St
CA 95817
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Wang S, Scharadin TM, Zimmermann M, Malfatti MA, Turteltaub KW, de Vere White R, Pan CX, Henderson PT. Correlation of platinum cytotoxicity to drug-DNA adduct levels in a breast cancer cell line panel. Chem Res Toxicol. 2018 Nov 01. PMID: 30381944.
      View in: PubMed
    2. Dall'Era MA, De Vere White RW. New Insights into Ejaculatory Frequency and Prostate Cancer Risk: Association, Causation, or What Do We Have to Lose? Eur Urol. 2018 Aug 31. PMID: 30177292.
      View in: PubMed
    3. Wang M, Yao LC, Cheng M, Cai D, Martinek J, Pan CX, Shi W, Ma AH, De Vere White RW, Airhart S, Liu ET, Banchereau J, Brehm MA, Greiner DL, Shultz LD, Palucka K, Keck JG. Humanized mice in studying efficacy and mechanisms of PD-1-targeted cancer immunotherapy. FASEB J. 2018 Mar; 32(3):1537-1549. PMID: 29146734.
      View in: PubMed
    4. Wang F, Zhang H, Ma AH, Yu W, Zimmermann M, Yang J, Hwang SH, Zhu D, Lin TY, Malfatti M, Turteltaub KW, Henderson PT, Airhart S, Hammock BD, Yuan J, de Vere White RW, Pan CX. COX-2/sEH Dual Inhibitor PTUPB Potentiates the Antitumor Efficacy of Cisplatin. Mol Cancer Ther. 2018 Feb; 17(2):474-483. PMID: 29284644.
      View in: PubMed
    5. Lara PN, Heilmann AM, Elvin JA, Parikh M, de Vere White R, Gandour-Edwards R, Evans CP, Pan CX, Schrock AB, Erlich R, Ross JS, Stephens PJ, McPherson J, Miller VA, Ali SM. TMPRSS2-ERG fusions unexpectedly identified in men initially diagnosed with nonprostatic malignancies. JCO Precis Oncol. 2017; 2017. PMID: 29629426.
      View in: PubMed
    6. Gheibi P, Zeng S, Son KJ, Vu T, Ma AH, Dall'Era MA, Yap SA, de Vere White RW, Pan CX, Revzin A. Microchamber Cultures of Bladder Cancer: A Platform for Characterizing Drug Responsiveness and Resistance in PDX and Primary Cancer Cells. Sci Rep. 2017 Sep 25; 7(1):12277. PMID: 28947782.
      View in: PubMed
    7. Wang SS, Zimmermann M, Zhang H, Lin TY, Malfatti M, Haack K, Turteltaub KW, Cimino GD, de Vere White R, Pan CX, Henderson PT. A diagnostic microdosing approach to investigate platinum sensitivity in non-small cell lung cancer. Int J Cancer. 2017 08 01; 141(3):604-613. PMID: 28437852.
      View in: PubMed
    8. de Vere White R. Re: Management of Nonmuscle Invasive Bladder Cancer: A Comprehensive Analysis of Guidelines from the Unites States, Europe, and Asia. Eur Urol. 2017 04; 71(4):688. PMID: 28073601.
      View in: PubMed
    9. Zimmermann M, Wang SS, Zhang H, Lin TY, Malfatti M, Haack K, Ognibene T, Yang H, Airhart S, Turteltaub KW, Cimino GD, Tepper CG, Drakaki A, Chamie K, de Vere White R, Pan CX, Henderson PT. Microdose-Induced Drug-DNA Adducts as Biomarkers of Chemotherapy Resistance in Humans and Mice. Mol Cancer Ther. 2017 Feb; 16(2):376-387. PMID: 27903751.
      View in: PubMed
    10. Scharadin TM, Zhang H, Zimmermann M, Wang S, Malfatti MA, Cimino GD, Turteltaub K, de Vere White R, Pan CX, Henderson PT. Diagnostic Microdosing Approach to Study Gemcitabine Resistance. Chem Res Toxicol. 2016 11 21; 29(11):1843-1848. PMID: 27657672.
      View in: PubMed
    11. Wang S, Zhang H, Scharadin TM, Zimmermann M, Hu B, Pan AW, Vinall R, Lin TY, Cimino G, Chain P, Vuyisich M, Gleasner C, Mcmurry K, Malfatti M, Turteltaub K, de Vere White R, Pan CX, Henderson PT. Molecular Dissection of Induced Platinum Resistance through Functional and Gene Expression Analysis in a Cell Culture Model of Bladder Cancer. PLoS One. 2016; 11(1):e0146256. PMID: 26799320; PMCID: PMC4723083.
    12. Pan CX, Zhang H, Tepper CG, Lin TY, Davis RR, Keck J, Ghosh PM, Gill P, Airhart S, Bult C, Gandara DR, Liu E, de Vere White RW. Development and Characterization of Bladder Cancer Patient-Derived Xenografts for Molecularly Guided Targeted Therapy. PLoS One. 2015; 10(8):e0134346. PMID: 26270481; PMCID: PMC4535951.
    13. Gandara DR, Mack PC, Bult C, Li T, Lara PN, Riess JW, Astrow SH, Gandour-Edwards R, Cooke DT, Yoneda KY, Moore EH, Pan CX, Burich RA, David EA, Keck JG, Airhart S, Goodwin N, de Vere White RW, Liu ET. Bridging tumor genomics to patient outcomes through an integrated patient-derived xenograft platform. Clin Lung Cancer. 2015 May; 16(3):165-72. PMID: 25838158; PMCID: PMC4586173.
    14. Thieu W, Tilki D, de Vere White R, Evans CP. The role of microRNA in castration-resistant prostate cancer. Urol Oncol. 2014 Jul; 32(5):517-523. PMID: 24935732.
      View in: PubMed
    15. de Vere White R, Lara PN. Toward a common therapeutic framework in castration-resistant prostate cancer: a model for urologic oncology and medical oncology interaction. Urol Oncol. 2014 May; 32(4):380-2. PMID: 24316022; PMCID: PMC4444361.
    16. Lin TY, Zhang H, Luo J, Li Y, Gao T, Lara PN, de Vere White R, Lam KS, Pan CX. Multifunctional targeting micelle nanocarriers with both imaging and therapeutic potential for bladder cancer. Int J Nanomedicine. 2012; 7:2793-804. PMID: 22745542; PMCID: PMC3383352.
    17. Jung CJ, Iyengar S, Blahnik KR, Jiang JX, Tahimic C, Torok NJ, de vere White RW, Farnham PJ, Zern M. Human ESC self-renewal promoting microRNAs induce epithelial-mesenchymal transition in hepatocytes by controlling the PTEN and TGFß tumor suppressor signaling pathways. Mol Cancer Res. 2012 Jul; 10(7):979-91. PMID: 22622027; PMCID: PMC4166560.
    18. Vinall RL, Mahaffey CM, Davis RR, Luo Z, Gandour-Edwards R, Ghosh PM, Tepper CG, de Vere White RW. Dual blockade of PKA and NF-?B inhibits H2 relaxin-mediated castrate-resistant growth of prostate cancer sublines and induces apoptosis. Horm Cancer. 2011 Aug; 2(4):224-38. PMID: 21789713; PMCID: PMC3249648.
    19. Henderson PT, Li T, He M, Zhang H, Malfatti M, Gandara D, Grimminger PP, Danenberg KD, Beckett L, de Vere White RW, Turteltaub KW, Pan CX. A microdosing approach for characterizing formation and repair of carboplatin-DNA monoadducts and chemoresistance. Int J Cancer. 2011 Sep 15; 129(6):1425-34. PMID: 21128223; PMCID: PMC3145006.
    20. Catto JW, Alcaraz A, Bjartell AS, De Vere White R, Evans CP, Fussel S, Hamdy FC, Kallioniemi O, Mengual L, Schlomm T, Visakorpi T. MicroRNA in prostate, bladder, and kidney cancer: a systematic review. Eur Urol. 2011 May; 59(5):671-81. PMID: 21296484.
      View in: PubMed
    21. Lin TY, Zhang H, Wang S, Xie L, Li B, Rodriguez CO, de Vere White R, Pan CX. Targeting canine bladder transitional cell carcinoma with a human bladder cancer-specific ligand. Mol Cancer. 2011 Jan 27; 10(1):9. PMID: 21272294; PMCID: PMC3040722.
    22. Scosyrev E, Ely BW, Messing EM, Speights VO, Grossman HB, Wood DP, de Vere White RW, Vogelzang NJ, Trump DL, Natale RB, Tangen CM, Crawford ED, Thompson IM. Do mixed histological features affect survival benefit from neoadjuvant platinum-based combination chemotherapy in patients with locally advanced bladder cancer? A secondary analysis of Southwest Oncology Group-Directed Intergroup Study (S8710). BJU Int. 2011 Sep; 108(5):693-9. PMID: 21105991; PMCID: PMC3117124.
    23. Wang S, Zhang H, Malfatti M, de Vere White R, Lara PN, Turteltaub K, Henderson P, Pan CX. Gemcitabine causes minimal modulation of carboplatin-DNA monoadduct formation and repair in bladder cancer cells. Chem Res Toxicol. 2010 Nov 15; 23(11):1653-5. PMID: 21028869; PMCID: PMC2987236.
    24. Zhang H, Aina OH, Lam KS, de Vere White R, Evans C, Henderson P, Lara PN, Wang X, Bassuk JA, Pan CX. Identification of a bladder cancer-specific ligand using a combinatorial chemistry approach. Urol Oncol. 2012 Sep; 30(5):635-45. PMID: 20888272; PMCID: PMC4572726.
    25. de Vere White R, Hackman RM, Kugelmass J. The dogmas of nutrition and cancer: time for a second (and maybe third) look. Ann N Y Acad Sci. 2010 Mar; 1190:118-25. PMID: 20388142.
      View in: PubMed
    26. de Vere White R. Words of wisdom. Re: comparative effectiveness of minimally invasive vs open radical prostatectomy. Eur Urol. 2010 Feb; 57(2):355-6. PMID: 20116768.
      View in: PubMed
    27. DeVere White RW, Vinall RL, Tepper CG, Shi XB. MicroRNAs and their potential for translation in prostate cancer. Urol Oncol. 2009 May-Jun; 27(3):307-11. PMID: 19414119; PMCID: PMC2761743.
    28. deVere White RW, Lara PN, Goldman B, Tangen CM, Smith DC, Wood DP, Hussain MH, Crawford ED. A sequential treatment approach to myoinvasive urothelial cancer: a phase II Southwest Oncology Group trial (S0219). J Urol. 2009 Jun; 181(6):2476-80; discussion 2480-1. PMID: 19371909.
      View in: PubMed
    29. Bedolla RG, Wang Y, Asuncion A, Chamie K, Siddiqui S, Mudryj MM, Prihoda TJ, Siddiqui J, Chinnaiyan AM, Mehra R, de Vere White RW, Ghosh PM. Nuclear versus cytoplasmic localization of filamin A in prostate cancer: immunohistochemical correlation with metastases. Clin Cancer Res. 2009 Feb 01; 15(3):788-96. PMID: 19188148; PMCID: PMC2666194.
    30. Barkauskas DA, An HJ, Kronewitter SR, de Leoz ML, Chew HK, de Vere White RW, Leiserowitz GS, Miyamoto S, Lebrilla CB, Rocke DM. Detecting glycan cancer biomarkers in serum samples using MALDI FT-ICR mass spectrometry data. Bioinformatics. 2009 Jan 15; 25(2):251-7. PMID: 19073586; PMCID: PMC2639011.
    31. de Vere White R. Re: defining optimal therapy for muscle-invasive bladder cancer. Eur Urol. 2008 Jun; 53(6):1295-6. PMID: 18471557.
      View in: PubMed
    32. de Leoz ML, An HJ, Kronewitter S, Kim J, Beecroft S, Vinall R, Miyamoto S, de Vere White R, Lam KS, Lebrilla C. Glycomic approach for potential biomarkers on prostate cancer: profiling of N-linked glycans in human sera and pRNS cell lines. Dis Markers. 2008; 25(4-5):243-58. PMID: 19126968; PMCID: PMC3827814.
    33. Hah SS, Sumbad RA, de Vere White RW, Turteltaub KW, Henderson PT. Characterization of oxaliplatin-DNA adduct formation in DNA and differentiation of cancer cell drug sensitivity at microdose concentrations. Chem Res Toxicol. 2007 Dec; 20(12):1745-51. PMID: 18001055.
      View in: PubMed
    34. Vinall RL, Hwa K, Ghosh P, Pan CX, Lara PN, de Vere White RW. Combination treatment of prostate cancer cell lines with bioactive soy isoflavones and perifosine causes increased growth arrest and/or apoptosis. Clin Cancer Res. 2007 Oct 15; 13(20):6204-16. PMID: 17947488.
      View in: PubMed
    35. de Vere White RW. Finasteride for chemoprevention of prostate cancer: why has it not been embraced? J Clin Oncol. 2007 Jul 20; 25(21):2999-3000. PMID: 17634478.
      View in: PubMed
    36. Tepper CG, Vinall RL, Wee CB, Xue L, Shi XB, Burich R, Mack PC, de Vere White RW. GCP-mediated growth inhibition and apoptosis of prostate cancer cells via androgen receptor-dependent and -independent mechanisms. Prostate. 2007 Apr 01; 67(5):521-35. PMID: 17252539.
      View in: PubMed
    37. Grossman HB, Tangen CM, Cordon-Cardo C, Cote R, Waldman FM, De Vere White RW, Karnad AB, Glode M, Crawford ED. Evaluation of Ki67, p53 and angiogenesis in patients enrolled in a randomized study of neoadjuvant chemotherapy with or without cystectomy: a Southwest Oncology Group Study. Oncol Rep. 2006 Oct; 16(4):807-10. PMID: 16969498.
      View in: PubMed
    38. Lara PN, de Vere White R. Accrual issues in genitourinary cancer clinical trials. Urol Oncol. 2006 Sep-Oct; 24(5):379-83. PMID: 16962485.
      View in: PubMed
    39. Burke PA, Gregg JP, Bakhtiar B, Beckett LA, Denardo GL, Albrecht H, De Vere White RW, De Nardo SJ. Characterization of MUC1 glycoprotein on prostate cancer for selection of targeting molecules. Int J Oncol. 2006 Jul; 29(1):49-55. PMID: 16773184.
      View in: PubMed
    40. Hah SS, Stivers KM, de Vere White RW, Henderson PT. Kinetics of carboplatin-DNA binding in genomic DNA and bladder cancer cells as determined by accelerator mass spectrometry. Chem Res Toxicol. 2006 May; 19(5):622-6. PMID: 16696564.
      View in: PubMed
    41. Vinall RL, Tepper CG, Shi XB, Xue LA, Gandour-Edwards R, de Vere White RW. The R273H p53 mutation can facilitate the androgen-independent growth of LNCaP by a mechanism that involves H2 relaxin and its cognate receptor LGR7. Oncogene. 2006 Mar 30; 25(14):2082-93. PMID: 16434975.
      View in: PubMed
    42. You Z, Shi XB, DuRaine G, Haudenschild D, Tepper CG, Lo SH, Gandour-Edwards R, de Vere White RW, Reddi AH. Interleukin-17 receptor-like gene is a novel antiapoptotic gene highly expressed in androgen-independent prostate cancer. Cancer Res. 2006 Jan 01; 66(1):175-83. PMID: 16397230.
      View in: PubMed
    43. Javidan J, Deitch AD, Shi XB, de Vere White RW. The androgen receptor and mechanisms for androgen independence in prostate cancer. Cancer Invest. 2005; 23(6):520-8. PMID: 16203660.
      View in: PubMed
    44. Wetherill YB, Fisher NL, Staubach A, Danielsen M, de Vere White RW, Knudsen KE. Xenoestrogen action in prostate cancer: pleiotropic effects dependent on androgen receptor status. Cancer Res. 2005 Jan 01; 65(1):54-65. PMID: 15665279.
      View in: PubMed
    45. Shi XB, Gandour-Edwards R, Beckett LA, Deitch AD, de Vere White RW. A modified yeast assay used on archival samples of localized prostate cancer tissue improves the detection of p53 abnormalities and increases their predictive value. BJU Int. 2004 Nov; 94(7):996-1002. PMID: 15541116.
      View in: PubMed
    46. Wu X, Obata T, Khan Q, Highshaw RA, De Vere White R, Sweeney C. The phosphatidylinositol-3 kinase pathway regulates bladder cancer cell invasion. BJU Int. 2004 Jan; 93(1):143-50. PMID: 14678387.
      View in: PubMed
    47. Shi XB, Ma AH, Xia L, Kung HJ, de Vere White RW. Functional analysis of 44 mutant androgen receptors from human prostate cancer. Cancer Res. 2002 Mar 01; 62(5):1496-502. PMID: 11888926.
      View in: PubMed
    48. Eandi JA, de Vere White RW, Tunuguntla HS, Bohringer CH, Evans CP. Can single dose preoperative intrathecal morphine sulfate provide cost-effective postoperative analgesia and patient satisfaction during radical prostatectomy in the current era of cost containment? Prostate Cancer Prostatic Dis. 2002; 5(3):226-30. PMID: 12496986.
      View in: PubMed
    49. Liu HL, Gandour-Edwards R, Lara PN, de Vere White R, LaSalle JM. Detection of low level HER-2/neu gene amplification in prostate cancer by fluorescence in situ hybridization. Cancer J. 2001 Sep-Oct; 7(5):395-403. PMID: 11693898.
      View in: PubMed
    50. deVere White RW, Deitch AD, Daneshmand S, Blumenstein B, Lowe BA, Sagalowsky AI, Smith JA, Schellhammer PF, Stanisic TH, Grossman HB, Messing E, Crissman JD, Crawford ED. The prognostic significance of S-phase analysis in stage Ta/T1 bladder cancer. A Southwest Oncology Group Study. Eur Urol. 2000 May; 37(5):595-600. PMID: 10765099.
      View in: PubMed
    51. Wilder RB, Hsiang JY, Ji M, Earle JD, de Vere White R. Preliminary results of three-dimensional conformal radiotherapy as salvage treatment for a rising prostate-specific antigen level postprostatectomy. Am J Clin Oncol. 2000 Apr; 23(2):176-80. PMID: 10776980.
      View in: PubMed
    52. deVere White RW, Deitch AD, Gumerlock PH, Shi XB. Use of a yeast assay to detect functional alterations in p53 in prostate cancer: review and future directions. Prostate. 1999 Oct 01; 41(2):134-42. PMID: 10477910.
      View in: PubMed
    53. de Vere White R, Meyers F, Chi SG, Chamberlain S, Siders D, Lee F, Stewart S, Gumerlock PH. Human androgen receptor expression in prostate cancer following androgen ablation. Eur Urol. 1997; 31(1):1-6. PMID: 9032526.
      View in: PubMed
    54. Nagabhushan M, Miller CM, Pretlow TP, Giaconia JM, Edgehouse NL, Schwartz S, Kung HJ, de Vere White RW, Gumerlock PH, Resnick MI, Amini SB, Pretlow TG. CWR22: the first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar. Cancer Res. 1996 Jul 01; 56(13):3042-6. PMID: 8674060.
      View in: PubMed
    55. Wertz IE, Deitch AD, Gumerlock PH, Gandour-Edwards R, Chi SG, de Vere White RW. Correlation of genetic and immunodetection of TP53 mutations in malignant and benign prostate tissues. Hum Pathol. 1996 Jun; 27(6):573-80. PMID: 8666367.
      View in: PubMed
    56. Deitch AD, de Vere White RW, Madewell BR. False DNA aneuploidy in canine and human neoplasms. Anticancer Res. 1993 Nov-Dec; 13(6A):2117-8. PMID: 8297122.
      View in: PubMed
    57. Wheeless LL, Badalament RA, de Vere White RW, Fradet Y, Tribukait B. Consensus review of the clinical utility of DNA cytometry in bladder cancer. Report of the DNA Cytometry Consensus Conference. Cytometry. 1993; 14(5):478-81. PMID: 8354118.
      View in: PubMed
    58. Hellstrom WJ, Tesluk H, Deitch AD, de Vere White RW. Comparison of flow cytometry to routine testicular biopsy in male infertility. Urology. 1990 Apr; 35(4):321-6. PMID: 2321325.
      View in: PubMed
    59. Wheeless LL, Coon JS, Cox C, Deitch AD, de Vere White RW, Koss LG, Melamed MR, O'Connell MJ, Reeder JE, Weinstein RS. Measurement variability in DNA flow cytometry of replicate samples. Cytometry. 1989 Nov; 10(6):731-8. PMID: 2582964.
      View in: PubMed
    60. Deitch AD, Strand MA, de Vere White RW. Deoxyribonucleic acid flow cytometry of benign prostatic disease. J Urol. 1989 Sep; 142(3):759-62. PMID: 2769856.
      View in: PubMed
    61. Gumerlock PH, Meyers FJ, Kokoris SP, Wong G, McCormick FP, de Vere White RW. RAS enzyme-linked immunoblot assay discriminates p21 species: a technique to dissect gene family expression. Anal Biochem. 1989 Jul; 180(1):158-68. PMID: 2683857.
      View in: PubMed
    62. Coon JS, Deitch AD, de Vere White RW, Koss LG, Melamed MR, Reeder JE, Weinstein RS, Wersto RP, Wheeless LL. Check samples for laboratory self-assessment in DNA flow cytometry. The National Cancer Institute's Flow Cytometry Network experience. Cancer. 1989 Apr 15; 63(8):1592-9. PMID: 2924266.
      View in: PubMed
    63. Coon JS, Deitch AD, de Vere White RW, Koss LG, Melamed MR, Reeder JE, Weinstein RS, Wersto RP, Wheeless LL. Interinstitutional variability in DNA flow cytometric analysis of tumors. The National Cancer Institute's Flow Cytometry Network Experience. Cancer. 1988 Jan 01; 61(1):126-30. PMID: 3334939.
      View in: PubMed
    64. de Vere White R, Paulson DF, Glenn JF. The clinical spectrum of prostate cancer. J Urol. 1977 Mar; 117(3):323-7. PMID: 839594.
      View in: PubMed